Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008



    Quarterly Reports Use Market Intelligence and Competitive Analysis from
Thomson Reuters to Highlight Developments in the Global Pharmaceutical
Industry
    PHILADELPHIA and LONDON, Jan. 21 /PRNewswire/ -- Thomson Reuters, the
world's leading source of intelligent information for businesses and
professionals, has announced the availability of three Pharma Matters reports
covering the time period July - September 2008. The quarterly Pharma Matters
series covers all aspects of the pharmaceutical pipeline, leveraging strategic
intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon
Premium(TM) and the Thomson Messaging Mapping System(SM).
    

    
    The Ones to Watch - A Thomson Reuters quarterly review of the latest
phase changes in the pharmaceutical pipeline, this report is based on
strategic data and analysis from Thomson Pharma, the world's leading
pharmaceutical competitive intelligence solution. In the report covering Q3
2008, the top five most promising drugs launched or receiving approval were:
    

    

    
    DRUG          DISEASE                     COMPANY
    

    
    Zeftera(TM)   Complicated skin and soft   Basilea Pharmaceutica
                  tissue infections
    

    
    Firazyr(R)    Hereditary angioedema       Jerini
    

    
    Bridion(R)    Reversal of muscle          Schering-Plough
                  relaxants
    

    
    Cleviprex(TM) Perioperative               The Medicines Company
                  hypertension
    

    
    Xarelto(R)    Venous thromboembolic       Bayer/Ortho-McNeil
                  events                      Pharmaceutical

    
    More analysis, as well as information on drugs entering clinical Phases
I, II and III are available in the full report:
http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.pdf.
    

    
    Movers and Shakers - This report covers the US generics industry using
data and analysis from Newport Horizon Premium, the critical product targeting
the global business development system. Analysis from the Q3 2008 report
includes:
    
    --  The pharmaceutical marketplace continued to demonstrate volatility,
and
        the pace of patent challenges showed no sign of slackening in the
third
        quarter of 2008.
    --  During the third quarter of 2008, final approvals were issued on only
        77 'A'-rated ANDAs, plummeting down from 142 the quarter before.
        First-time approvals of generic products by the FDA also dropped from
        11 to 8 this quarter.
    --  Seven new products (three combination products and four single active
        ingredient products) were subjected to paragraph IV challenges for the
        first time in Q3 2008, identical to the previous quarter.
    --  Indian groups were in first place in terms of ANDA approvals during Q3
        2008. Twelve India-based corporations received a total of 17 final
ANDA
        approvals.
    --  In the same time period, 11 US-based companies received a total of 15
        approvals, putting the U.S. in second place for this quarter.
    --  Mylan of the U.S. and Boehringer Ingelheim of Germany received the
most
        final ANDA approvals (seven each).

    
    To learn more about companies making their mark on the U.S. generics
market, click here to read the full report:
http://thomsonreuters.com/content/PDF/scientific/pharma/2008ms_q3.pdf
    

    
    Who is Making the Biggest Splash? - A Thomson Reuters expert review of
the organizations that are helping to shape professional opinions on drugs and
therapies, using the unique insights of the Thomson Message Mapping System. In
this quarterly review of the scientific literature on drugs and therapies,
Thomson Reuters assesses the quantity and quality of the materials published
by pharmaceutical companies, research institutions and other non-commercial
bodies. The top five of the 15 listed organizations that have made the biggest
impact as the leading sources of information on medical research from July -
September 2008 are:
    
    1. Novartis
    2. Bristol-Meyers Squibb
    3. Eli Lilly
    4. Pfizer
    5. AstraZeneca

    
    To see the complete list, as well as analysis and methodology, click here
to read the full report:
http://thomsonreuters.com/content/PDF/scientific/pharma/2008wmtbs_q3.pdf
    

    
    To sign up for the Thomson Reuters Pharma Matters series of publications
visit: http://scientific.thomsonreuters.com/forms/matters/
    

    About Thomson Reuters
    
    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to thomsonreuters.com.
    



    




For further information:

For further information: Sue Besaw, Manager, PR & Communications of
Thomson Reuters, +1-215-823-1840, susan.besaw@thomsonreuters.com Web Site:
http://www.thomsonreuters.com/


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890